MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2024.06.019

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2024

Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial.

Katada Chikatoshi, Yokoyama Tetsuji, Watanabe Akinori, Hara Hiroki, Yoshii Takako, Fujii Hirofumi, Yamaguchi Hironori, Nakajima Takako Eguchi, Izawa Naoki, Ando Takayuki, Nomura Motoo, Kojima Takashi, Yamashita Keishi, Kawakami Shogo, Ishiyama Hiromichi, Inoue Yusuke, Sakamoto Yasutoshi, Sasaki Hiroki, Ishikawa Hideki, Hosokawa Ayumu, Hamamoto Yasuo, Muto Manabu, Tahara Makoto, Koizumi Wasaburo

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: This study aimed to assess the viability of definitive chemoradiotherapy (dCRT) as an organ-preservation strategy for remarkable responders who were downstaged to stage IA after receiving induction chemotherapy for resectable esophageal squamous cell carcinoma (ESCC).

METHODS AND MATERIALS: Chemotherapy-naïve patients with resectable ESCC (stage IB-III, Union for International Cancer Control, International Cancer Control seventh edition) were eligible for the study. All patients received 3 cycles of docetaxel, cisplatin, and 5-FU (DCF) therapy (docetaxel 75 mg/m2 on day 1, cisplatin 75 mg/m2 on day 1, and 5-fluorouracil [5-FU] 750 mg/m2 on days 1-5, repeated every 3 weeks). Remarkable response was defined as a reduction in the tumor to T1, metastatic lymph nodes <1 cm on the short axis, and downstaging to stage IA after 3 cycles of DCF therapy. Remarkable responders then underwent dCRT, which included 2 courses of cisplatin 75 mg/m2 and 5-FU 1000 mg/m2 on days 1 to 4, repeated every 4 weeks, along with 50.4 Gy of concurrent radiation therapy. The primary endpoint was 1-year progression-free survival in remarkable responders following DCF therapy and subsequent dCRT. Secondary endpoints included 3-year overall survival (OS) and esophagectomy-free survival.

RESULTS

Of the 92 patients registered, 90 were analyzed. A remarkable response to 3 courses of DCF therapy was observed in 58.4% of patients. Among these responders, 89.8% achieved a complete response after dCRT. During the median follow-up period of 33 months (range, 1-85 months), the 1-year progression-free survival was 89.8% (95% confidence interval [CI], 77.2%-95.6%, primary endpoint), and the 3-year OS was 83.7%. The 3-year OS and esophagectomy-free survival rates in the analysis group were 74.1% and 45.3%, respectively. An 18F-fluorodeoxyglucose-positron emission tomography response after 2 courses of DCF therapy was significantly associated with OS (P = .0049).

CONCLUSIONS

In patients with resectable ESCC, dCRT for remarkable responders downstaging to stage IA after induction chemotherapy with 3 courses of DCF therapy is a feasible treatment option and provides an optimizing organ-preservation strategy of chemotherapy-based selection.

Для цитирования: Katada Chikatoshi, Yokoyama Tetsuji, Watanabe Akinori, Hara Hiroki, Yoshii Takako, Fujii Hirofumi, Yamaguchi Hironori, Nakajima Takako Eguchi, Izawa Naoki, Ando Takayuki, Nomura Motoo, Kojima Takashi, Yamashita Keishi, Kawakami Shogo, Ishiyama Hiromichi, Inoue Yusuke, Sakamoto Yasutoshi, Sasaki Hiroki, Ishikawa Hideki, Hosokawa Ayumu, Hamamoto Yasuo, Muto Manabu, Tahara Makoto, Koizumi Wasaburo. Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial.. International journal of radiation oncology, biology, physics. 2024. DOI: 10.1016/j.ijrobp.2024.06.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.